Company Overview

Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System to enable complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its surgical systems; progressive learning pathways to support the use of its technology; a complement of services to its customers, including support, installation, repair, and maintenance; and integrated digital capabilities providing unified and connected offerings, streamlining performance for hospitals with program-enhancing insights. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.

  • Name

    Intuitive Surgical, Inc.

  • CEO

    Dr. Gary S. Guthart Ph.D.

  • Website

    www.intuitive.com

  • Sector

    Health Care Equipment and Supplies

  • Year Founded

    1995

Profile

  • Market Cap

    $174.62B

  • EV

    $169.95B

  • Shares Out

    355.35M

  • Revenue

    $7,572.5M

  • Employees

    13,676

Margins

  • Gross

    66.86%

  • EBITDA

    31.51%

  • Operating

    25.79%

  • Pre-Tax

    29.46%

  • Net

    27.65%

  • FCF

    5.54%

Returns (5Yr Avg)

  • ROA

    12.46%

  • ROTA

    14.46%

  • ROE

    14.32%

  • ROCE

    14.4%

  • ROIC

    19.76%

Valuation (TTM)

  • P/E

  • P/B

  • EV/Sales

  • EV/EBITDA

  • P/FCF

  • EV/Gross Profit

Valuation (NTM)

  • Price Target

    $483.95

  • P/E

  • PEG

  • EV/Sales

  • EV/EBITDA

  • P/FCF

Financial Health

  • Cash

    $4,757.2M

  • Net Debt

    -$4,757.2M

  • Debt/Equity

    0.01

  • EBIT/Interest

Growth (CAGR)

  • Rev 3Yr

    13.62%

  • Rev 5Yr

    13.39%

  • Rev 10Yr

    14.06%

  • Dil EPS 3Yr

    9.24%

  • Dil EPS 5Yr

    11.5%

  • Dil EPS 10Yr

    15.71%

  • Rev Fwd 2Yr

    14.87%

  • EBITDA Fwd 2Yr

    17.67%

  • EPS Fwd 2Yr

    15.85%

  • EPS LT Growth Est

    17.84%

Dividends

  • Yield

  • Payout

  • DPS

  • DPS Growth 3Yr

  • DPS Growth 5Yr

  • DPS Growth 10Yr

  • DPS Growth Fwd 2Yr

NasdaqGS:ISRG